Corindus Vascular Robotics (CVRS) Stock Price, News & Analysis

Company Overview

Corindus Vascular Robotics was a medical technology company that developed robotic-assisted systems for interventional cardiology and vascular procedures. Its primary product, the CorPath GRX platform, was designed to help physicians perform percutaneous coronary and peripheral vascular interventions with robotic control.

The CorPath GRX system provided computer-assisted control of guidewires, catheters and other interventional devices. The platform was intended to improve procedural precision and consistency while allowing physicians to work from a radiation-shielded workstation, reducing exposure to scattered radiation during certain procedures. Corindus also pursued capabilities for remote and teleoperated interventions.

Corindus served hospitals and cardiovascular treatment centers, primarily in the United States and other international markets where its technology received regulatory authorization. The company was led by Mark Toland as president and chief executive officer during its period as a public company. Siemens Healthineers acquired Corindus in 2019, after which Corindus operated as part of Siemens Healthineers’ advanced therapies business; CVRS is therefore a historical trading symbol rather than an independently listed company today.

Key Stats

• Today's Range: $4.27 to $4.27
• 50-Day Range: $4.27 to $4.27
• 52-Week Range: $0.78 to $4.40
• Volume: N/A
• Average Volume: 1.99 million shs
• Market Capitalization: $891.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/07/2018
• Today: 9/26/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSEAMERICAN:CVRS
• Previous Symbol: NYSEMKT:CVRS
• CIK: N/A
• Web: www.corindus.com
• Phone: +1-508-6533335
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 208,685,000
• Free Float: N/A
• Market Cap: $891.08 million
• Optionable: Not Optionable
• Beta: N/A